Factor v Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome

Critical Care Medicine

Volumn 36, Issue 6, 2008, Pages 1776-1779

  Adamzik, Michael ^a   Frey, Ulrich H ^a   Riemann, Kathrin ^a   Sixt, Stephan ^a   Lehmann, Nils ^a   Siffert, Winfried ^a   Peters, Jürgen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acute respiratory distress syndrome; Factor V Leiden; Protein C; Thrombin

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLUTAMINE; BLOOD CLOTTING FACTOR 5;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GERMANY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TERTIARY HEALTH CARE; ACTIVATED PROTEIN C RESISTANCE; APACHE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; APACHE; ARGININE; COHORT STUDIES; FACTOR V; FEMALE; GENOTYPE; GLUTAMINE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES;

EID: 45149107730     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318174373d     Document Type: Article

References (31)

1. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European Consensus Conference on acute respiratory distress syndrome: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994; 9:72-81
2. Johnson K, Aarden L, Choi Y, et al: The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87:5051-5060
3. Menges T, Hermans PW, Little SG, et al: Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357: 1096-1097
4. Aird WC: Sepsis and coagulation. Crit Care Clin 2005; 21:417-431
5. Aird WC: Natural anticoagulant inhibitors: Activated protein C. Best Pract Res Clin Haematol 2004; 17:161-182
6. Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004; 32:S239-S246
7. Weiler H, Kerlin B, Lytle MC: Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Crit Care Med 2004; 32:S233-S238
8. Svensson PJ, Zoller B, Mattiasson I, et al: The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997; 241: 379-385
9. Pawar AR, Shetty S, Ghosh K, et al: How old is factor V Leiden mutation? Thromb Haemost 2001; 86:1591-1592
10. Pawar A, Ghosh K, Shetty S, et al: High frequency of factor V Leiden mutation in Parsis, a highly endogamous population in India. Thromb Haemost 2000; 83:965
11. Kerlin BA, Yan SB, Isermann BH, et al: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092
12. Adamzik M, Frey U, Sixt S, et al: ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J 2007; 29:482-488
13. Bone RC, Sprung CL, Sibbald WJ: Definitions for sepsis and organ failure. Crit Care Med 1992; 20:724-726
14. Le G Jr, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multi-center study. JAMA 1993; 270:2957-2963
15. Ferreira FL, Bota DP, Bross A, et al: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286:1754-1758
16. Espana F, Medina P, Navarro S, et al: The multifunctional protein C system. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:119-131
17. Esmon CT: The roles of protein C and throm- bomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264:4743-4746
18. Esmon NL, Esmon CT: Protein C and the endothelium. Semin Thromb Hemost 1988; 14:210-215
19. Walker FJ, Scandella D, Fay PJ: Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem 1990; 265:1484-1489
20. Bajzar L, Nesheim ME, Tracy PB: The profi-brinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88:2093-2100
21. Boehme MW, Deng Y, Raeth U, et al: Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies. Immunology 1996; 87:134-140
22. Taylor FB Jr, Peer GT, Lockhart MS, et al: Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685-1688
23. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
24. Taylor FB Jr, Chang A, Hinshaw LB, et al: A model for thrombin protection against endotoxin. Thromb Res 1984; 36:177-185
25. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878
26. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
27. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67
28. Van't Veer C, Golden NJ, Kalafatis M, et al: An in vitro analysis of the combination of hemophilia A and factor V(Leiden). Blood 1997; 90:3067-3072
29. Van't Veer C, Kalafatis M, Bertina RM, et al: Increased tissue factor-initiated prothrombin activation as a result of the Arg506Gln mutation in factor V Leiden. J Biol Chem 1997; 272:20721-20729
30. Kondaveeti S, Hibberd ML, Booy R, et al: Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999; 18:893-896
31. Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al: Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29:577-580